Inside MedSpa — Never miss a recall or a rule change.

RHA Redensity Eye gains FDA clearance for infraorbital hollowing

Revance and Teoxane announced FDA approval of RHA Redensity Eye, a resilient hyaluronic acid filler designed specifically for under-eye hollowing. This is the first HA filler cleared for this indication with real-time imaging guidance.

Why it matters — Under-eye hollowing is a high-volume, high-margin procedure in most practices. RHA's crosslinked structure and lower G' modulus make it rheologically distinct from traditional HA fillers—it resists diffusion better in the delicate infraorbital space, reducing the risk of malar edema and migration. This creates a clinical advantage over off-label Juvéderm or Restylane use and gives you a defensible, FDA-cleared protocol. Expect Allergan and Galderma to respond with their own under-eye-specific claims or label expansions.

Evolus Q2 revenue up 21%; raises 2026 outlook on Jeuveau momentum

Evolus reported Q2 2026 revenue growth of 21% year-over-year, delivered its third consecutive quarter of positive adjusted EBITDA, and raised full-year 2026 guidance. The company cited strong Jeuveau (prabotulinumtoxinA) adoption and international expansion.

Allergan SkinMedica program terms changed; rebate/loyalty structure shifted

The public SkinMedica/Allergan brand terms page has been updated since last review, signaling a change in manufacturer loyalty and rebate terms. No formal announcement was made.

Juvéderm Day promotional discount returns; filler pricing pressure continues

Allergan has relaunched its Juvéderm Day promotional discount campaign, offering significant price reductions on filler products during the promotional window.